Lukas Huber’s Post

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/pIvZmK. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/fzygaI. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/lwt076. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

🎉 Welcome KalVista Pharmaceuticals, Inc. to the Greater Zurich Area! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/rtMvna. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

🎉 #WelcomeToGreaterZurich, KalVista Pharmaceuticals, Inc.! 🧬 KalVista, a leading #biotech company specializing in the discovery and development of small molecule protease inhibitors, has recently established its Swiss subsidiary in Zug. This marks a significant milestone as they continue to expand their global presence. 📍 The #GreaterZurichArea is a beacon for #biotechnology and pharmaceutical #innovation, home to pioneering companies and top research institutions. Supported by a liberal economy and robust academic-industry partnerships, the region stands as one of Europe's leading life science centers. 🌐 This environment not only attracts some of the world's most talented scientists and entrepreneurs but also fosters a culture of innovation that is essential for business growth. As a result, the Greater Zurich Area is a prime location for expansion, offering an ideal setting for companies like KalVista to advance #healthcare and #technology. 🔍 Ready to join this vibrant ecosystem? Find out why biotech companies thrive in the Greater Zurich Area: https://okt.to/o2tybU. Economic Promotion Canton of Zug, Kanton Zug #LifeSciences #BusinessExpansion #whySwitzerland

Great achievements from our PhD candidates! Three of PhD students supervised by Dr. Himanshu Kaul have been accepted to the Conception X Accelerator programme. They are Bo Tian, Mael Derjean (Respiratory Sciences), and Mahesh Kumar Ola. Conception X will provide them training to commercialise the 3 different technologies they are developing in the Kaul Lab. Bo is developing software to help industries undertake reconfiguration rapidly and economically, Mael is developing a protocol to create ‘lung organoids’ that will help pharmaceutical companies understand drug pharmacodynamics, and Mahesh is engineering a multiscale virtual patient that will enable efficacious clinical decision-making. #engineering #phd #commercialisation

𝗥𝗼𝗰𝗵𝗲 𝗮𝗻𝗱 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀: 𝗕𝗮𝘀𝗲𝗹'𝘀 𝗥&𝗜 𝗽𝗼𝘄𝗲𝗿𝗵𝗼𝘂𝘀𝗲𝘀 Both research and innovation (R&I) are key drivers of a successful drug pipeline. With this in mind, we at the CIEB Universität Basel analyzed the quality of large pharma companies' R&I activities. Here are our key findings: - Basel-based 𝐑𝐨𝐜𝐡𝐞 is very strong in R&I, as evidenced by a much higher than average number of citations per scientific paper and patent. Basel-based 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 is also above average on both counts. - 𝐀𝐦𝐠𝐞𝐧, 𝐆𝐢𝐥𝐞𝐚𝐝 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬, 𝐀𝐬𝐭𝐫𝐚 𝐙𝐞𝐧𝐞𝐜𝐚, 𝐚𝐧𝐝 𝐁𝐫𝐢𝐬𝐭𝐨𝐥 𝐌𝐲𝐞𝐫𝐬 𝐒𝐪𝐮𝐢𝐛𝐛 also have both highly cited scientific papers and patents. 𝐀𝐦𝐠𝐞𝐧 in particular has received many citations for its patents. - 𝐍𝐨𝐯𝐨 𝐍𝐨𝐫𝐝𝐢𝐬𝐤, 𝐏𝐟𝐢𝐳𝐞𝐫, 𝐁𝐚𝐲𝐞𝐫, 𝐚𝐧𝐝 𝐆𝐥𝐚𝐱𝐨 𝐒𝐦𝐢𝐭𝐡 𝐊𝐥𝐢𝐧𝐞 have highly cited scientific papers but not as many highly cited patents. -> In summary, our analysis confirms that 𝐑𝐨𝐜𝐡𝐞 and 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 are among the leaders in producing highly cited and influential R&I. These results point to a positive future for Basel in drug development and healthcare innovation.   Notes: Data include company affiliations. For example, Genentech is assigned to Roche. We used all USPTO patents and scientific papers from the Scopus database attributed to the pharmaceutical field between 2013 and 2022. For patents, we used docdb family citations, and for papers, we weighted citations by author (as papers often contain a larger number of authors from different institutions). #BaselInnovation #pharma #research #innovation Christian Rutzer Till Schmidlin Valentina Francia, PhD Interpharma

"𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐢𝐧𝐠 𝐧𝐞𝐰 𝐟𝐫𝐨𝐧𝐭𝐢𝐞𝐫𝐬 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐲, 𝐭𝐨𝐠𝐞𝐭𝐡𝐞𝐫 𝐰𝐞 𝐢𝐠𝐧𝐢𝐭𝐞 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧, 𝐜𝐞𝐥𝐞𝐛𝐫𝐚𝐭𝐞 𝐚𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬, 𝐚𝐧𝐝 𝐢𝐧𝐬𝐩𝐢𝐫𝐞 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐠𝐥𝐨𝐛𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡." Dear #linkedinconnections, 🙏It was an absolute honor to be the first Keynote speaker during the very first day of the 3rd International Pharma Summit on "Drug Discovery & Community Trial", organized by BioLeagues and Association of Pharmaceutical Research . 🫶This prestigious conference, which started on 27th and will continue till today ie 28th of March 2024 in the beautiful city of #Bali, #Indonesia in #hybrid mode, aims to bring together the brightest minds in the field of pharmacology. 🙏My gratitude to the management of Association of Pharmaceutical Research and. BioLeagues group for inviting me and giving me this opportunity and honour .. 🤜🤛The primary objective of this summit is to create a platform where from across the Globe the leading academic scientists, researchers and scholars are and will exchange their incredible research and ideas, thus sharing their groundbreaking works and research results. ⭐ In this conference, the diverse range of topics which are getting covered by all the esteemed faculties, Keynote speakers & Guest speakers reflect our commitment to exploring all aspects of pharmacology in the entire Globe at all levels, which includes.. 👍𝑹𝒆𝒄𝒐𝒈𝒏𝒊𝒛𝒊𝒏𝒈 𝒕𝒉𝒆 𝑹𝒐𝒍𝒆 𝒐𝒇 𝑻𝒆𝒄𝒉𝒏𝒐𝒍𝒐𝒈𝒚 𝒊𝒏 𝑫𝒓𝒖𝒈 𝑫𝒊𝒔𝒄𝒐𝒗𝒆𝒓𝒚 👍𝑨𝒅𝒅𝒓𝒆𝒔𝒔𝒊𝒏𝒈 𝑬𝒕𝒉𝒊𝒄𝒂𝒍 𝑪𝒐𝒏𝒔𝒊𝒅𝒆𝒓𝒂𝒕𝒊𝒐𝒏𝒔 𝒂𝒏𝒅 𝑬𝒏𝒔𝒖𝒓𝒊𝒏𝒈 𝑷𝒂𝒕𝒊𝒆𝒏𝒕 𝑺𝒂𝒇𝒆𝒕𝒚 👍𝑪𝒆𝒍𝒆𝒃𝒓𝒂𝒕𝒊𝒏𝒈 𝑨𝒄𝒉𝒊𝒆𝒗𝒆𝒎𝒆𝒏𝒕𝒔 👍𝑬𝒏𝒄𝒐𝒖𝒓𝒂𝒈𝒊𝒏𝒈 𝒀𝒐𝒖𝒏𝒈 𝑹𝒆𝒔𝒆𝒂𝒓𝒄𝒉𝒆𝒓𝒔 🫶In a nutshell, let us embrace the opportunities being presented by esteemed Faculties from across the 🌍 globe which has showcase the new paradigm shift in Pharmaceutical sciences.. ✅Together, we can push the boundaries of pharmacology through collaboration, innovation and the responsible pursuit of knowledge. 🙌𝐀𝐬 𝐰𝐞 𝐠𝐚𝐭𝐡𝐞𝐫 𝐢𝐧 𝐁𝐚𝐥𝐢 𝐚𝐧𝐝 𝐚𝐥𝐬𝐨 𝐢𝐧 𝐇𝐲𝐛𝐫𝐢𝐝 𝐦𝐨𝐝𝐞, 𝐥𝐞𝐭 𝐮𝐬 𝐛𝐞 𝐢𝐧𝐬𝐩𝐢𝐫𝐞𝐝 𝐚𝐧𝐝 𝐟𝐮𝐞𝐥 𝐨𝐮𝐫 𝐩𝐚𝐬𝐬𝐢𝐨𝐧 𝐟𝐨𝐫 𝐢𝐦𝐩𝐫𝐨𝐯𝐢𝐧𝐠 𝐠𝐥𝐨𝐛𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡. #pkrajputtalks #theleaderswithladders #thejourneycontinues #pharmaceuticalssciences #pharmaceutics #innovation #drugdiscovery #ai #machinelearning #technology

The BioVerse EP006 - #Physician Scientists' Checklist for Successful #Global #Clinical Development has concluded with a highly engaging and productive discussion. Led by a panel of experienced pharmaceutical industry veterans, including Axel Hoos, David Weinstock, Francisco Leon, and Li Yan, the session delved into the insights behind their #trackrecord of #approved drugs. They also shared the secrets behind some turnaround stories and offered advice, particularly to #emerging #biotechs, including those in #China, aspiring to develop #innovativemedicines for the #globalmarket and patients worldwide. 🌟 Two pivotal #takeaways emerged: the importance of following the #science and cultivating trusted relationships. With real-world examples (#realworldevidence #realworlddata) provided by the panelists for immediate illustration, the objective of #empowering the #community to advance with increased confidence was successfully achieved. Ipilimumab was highlighted to underscore the critical role of following the #science in steering #clinicaldevelopment programs. This involves introducing #novelmechanisms and #paradigms to #investigators, #regulators, and #patients. Ensuring alignment and #stakeholder #endorsement relies heavily on the "follow the science" principle, extending to areas such as cross-therapeutic #repurposing, learning from "failed" trials, and reverse translation. The significance of building and maintaining #trusted #relationships was highlighted for the smooth #execution of clinical development strategies, effective partnerships with various parties, and successful #business #collaborations. The panelists provided vivid examples to illustrate the value of fostering strong relationships. As closing remarks, the panelists also offered valuable advice to #Chinese biotech firms: 1️⃣ Biotechs should establish a global clinical development plan from the outset, rather than altering it as an afterthought. 2️⃣ Emphasis was placed on the critical importance of high-quality #CMC, particularly for clinical-stage #assets. 3️⃣ The recurring emphasis on cultivating strong and quality relationships was mentioned once more. Revisit the episode by clicking here: https://lnkd.in/erZVwM9y. Also, welcome to join the upcoming IO360 at #NYC (https://io360summit.com/) with InScienceWeTrust Community on Feb 27-29 and @SAPA-GP annual conference at #GreaterPhiladelphia (https://qrco.de/benTPs) on March 8-9!

🛎 Would you like to learn about the "Physician Scientists' Checklist to Conduct Successful Clinical Development for the Global Market"? Please come join our upcoming BioVerse monthly Webinar episode! ⏳ Date and Time: Wed, Feb 14, 8:30 AM - 9:30 AM (EST) 9:30 PM - 10:30 PM (BJT) Register free at: https://lnkd.in/gtgJbJB4 We invited a panel of decorated physician-scientists who have brought about a dozen drugs to the market and have collectively accumulated 70 years of industry drug development experience, they are: Axel Hoos, MD/PhD, Physician Scientist, Biopharma leader, Entrepreneur  Francisco Leon, MD/PhD, Immunologist, Founder & CEO of Tolerance Bio David Weinstock, Vice President of Discovery Oncology at Merck Li Yan, MD/PhD, Seasoned drug developer and Adjunct Professor at Yonsei University Host: Leon 'Jun' T. Ph.D., Founder of InScienceWeTrust Community & ISWT-BioAdvisory This is the ideal panel to share the “Checklists”, or best practices, behind this stellar track record of approved drugs. Additionally, they will also share the secret sources of some turn-around stories and their advice to emerging biotechs, especially the China biotechs, that aspire to develop innovative medicines for the global market and patients around the world. #BioVerse: Where Science Spark Business is a monthly webinar series hosted by SAPA-GP (Sino-American Pharmaceutical Professionals Association -Greater Philadelphia) and InScienceWeTrust Community. #clinical #clinicaltrials #clinicalresearch #clinicaldevelopment #globalmarkets #biotech #physicianscientist #physicians #businessdevelopment #clinicaldevelopmentplan #cdp #cdps #webinar #freewebinars #innovativemedicine #drugapproval